Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions

Fei Guo, Brittany C. Parker Kerrigan, Da Yang, Limei Hu, Ilya Shmulevich, Anil K. Sood, Fengxia Xue, Wei ZhangJournal of Hematology & Oncology 2014 · DOI

Abstract

Epithelial-to-mesenchymal transition (EMT) and its reverse, mesenchymal-to-epithelial transition (MET), are fundamental processes in embryogenesis and cancer progression. While signaling pathways and transcriptional networks are well-known drivers, recent research highlights a critical post-transcriptional layer. This review synthesizes how long non-coding RNAs (lncRNAs) and microRNAs (miRNAs)—including the miR-200 family, miR-101, and miR-506—form intricate regulatory networks that control these transitions. These non-coding molecules often interact with epigenetic machinery and transcription factors, creating feedback loops that determine a cell's metastatic potential. Understanding these networks identifies novel therapeutic targets for treating advanced cancers.

Introduction: The Metastatic Switch

Metastasis is the primary cause of cancer-related mortality. It involves a dynamic phenotypic plasticity where cells transition between a stationary epithelial state and a migratory mesenchymal state. Epithelial-to-Mesenchymal Transition (EMT) enables cells to detach from the primary tumor and invade surrounding tissues, while Mesenchymal-to-Epithelial Transition (MET) allows disseminated cells to colonize distant organs.

The Regulatory Landscape of EMT and MET

While transcription factors like Snail, Twist, and ZEB are known "master regulators," the post-transcriptional network acts as a "dimmer switch," providing precision control over the transition. This layer involves complex interactions between external signals and internal molecular machinery.

Figure 1: The regulatory network governing EMT and MET, illustrating the interplay between external signals, transcription factors, and post-transcriptional regulators like miRNAs and lncRNAs.

Key regulatory mechanisms include:

  • The miR-200/ZEB Feedback Loop: A double-negative feedback loop between the miR-200 family and ZEB1/2 transcription factors creates a bistable switch. miR-200 suppresses ZEB, maintaining the epithelial state, while ZEB can suppress miR-200 expression to drive EMT.
  • lncRNAs as Epigenetic Scaffolds: lncRNAs like HOTAIR act as physical scaffolds that recruit epigenetic modifiers (e.g., Polycomb Repressive Complex 2) to specific genomic sites, effectively "reprogramming" the cell's chromatin to favor a migratory phenotype.
  • Epigenetic Silencing: Many EMT-suppressing miRNAs are silenced in cancer through DNA methylation of their promoter regions, suggesting that demethylating agents could potentially restore these natural "brakes" on metastasis.

Clinical Findings and Therapeutic Potential

The review highlights several non-coding RNAs with significant clinical correlations across various cancer types:

  • HOTAIR: High levels are strongly associated with lymph node metastasis and advanced tumor stages in gastric and breast cancers.
  • MALAT-1: This lncRNA promotes EMT via the Wnt signaling pathway. In mouse models, targeting MALAT-1 with antisense oligonucleotides significantly reduced lung metastasis.
  • miR-506: Identified as a potent EMT inhibitor in ovarian cancer, it targets SNAI2 and vimentin. Nanoparticle delivery of miR-506 in vivo led to substantial tumor reduction.

Challenges and Future Directions

Despite the promise of targeting these networks, several hurdles remain. The function of a specific miRNA can be highly context-dependent, acting as a suppressor in one tissue and a promoter in another. Additionally, while EMT is the focus of much research, MET—the "settling" phase—is equally critical for colonization but less understood. Inhibiting MET might prevent colonization but could inadvertently leave cells in a highly invasive, migratory state. Future work must focus on precise therapeutic delivery systems and rigorous in vivo validation of these complex regulatory loops within the tumor microenvironment.

Conclusion

The post-transcriptional regulatory network represents a frontier in oncology. By mapping the interactions between miRNAs, lncRNAs, and traditional signaling pathways, researchers are uncovering high-precision targets that could one day stop cancer in its tracks.

Summary updated

Abstract

Epithelial-to-mesenchymal transition (EMT) and its reverse process, mesenchymal-to-epithelial transition (MET), play important roles in embryogenesis, stem cell biology, and cancer progression. EMT can be regulated by many signaling pathways and regulatory transcriptional networks. Furthermore, post-transcriptional regulatory networks regulate EMT; these networks include the long non-coding RNA (lncRNA) and microRNA (miRNA) families. Specifically, the miR-200 family, miR-101, miR-506, and several lncRNAs have been found to regulate EMT. Recent studies have illustrated that several lncRNAs are overexpressed in various cancers and that they can promote tumor metastasis by inducing EMT. MiRNA controls EMT by regulating EMT transcription factors or other EMT regulators, suggesting that lncRNAs and miRNA are novel therapeutic targets for the treatment of cancer. Further efforts have shown that non-coding-mediated EMT regulation is closely associated with epigenetic regulation through promoter methylation (e.g., miR-200 or miR-506) and protein regulation (e.g., SET8 via miR-502). The formation of gene fusions has also been found to promote EMT in prostate cancer. In this review, we discuss the post-transcriptional regulatory network that is involved in EMT and MET and how targeting EMT and MET may provide effective therapeutics for human disease.
BibTeX
@article{guo2014post,
  author = {Fei Guo and Brittany C. Parker Kerrigan and Da Yang and Limei Hu and Ilya Shmulevich and Anil K. Sood and Fengxia Xue and Wei Zhang},
  title = {{Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions}},
  journal = {Journal of Hematology \& Oncology},
  year = {2014},
  doi = {10.1186/1756-8722-7-19},
}
Figure